NZ576467A - Smoothened polypeptides and methods of use - Google Patents

Smoothened polypeptides and methods of use

Info

Publication number
NZ576467A
NZ576467A NZ576467A NZ57646707A NZ576467A NZ 576467 A NZ576467 A NZ 576467A NZ 576467 A NZ576467 A NZ 576467A NZ 57646707 A NZ57646707 A NZ 57646707A NZ 576467 A NZ576467 A NZ 576467A
Authority
NZ
New Zealand
Prior art keywords
methods
smoothened
disclosed
polypeptides
smoothened polypeptides
Prior art date
Application number
NZ576467A
Other languages
English (en)
Inventor
Nadya Tarasova
Michael Dean
Hong Lou
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Publication of NZ576467A publication Critical patent/NZ576467A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ576467A 2006-10-31 2007-10-30 Smoothened polypeptides and methods of use NZ576467A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85542206P 2006-10-31 2006-10-31
PCT/US2007/083027 WO2008070357A2 (en) 2006-10-31 2007-10-30 Smoothened polypeptides and methods of use

Publications (1)

Publication Number Publication Date
NZ576467A true NZ576467A (en) 2012-03-30

Family

ID=39492945

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ576467A NZ576467A (en) 2006-10-31 2007-10-30 Smoothened polypeptides and methods of use

Country Status (13)

Country Link
US (3) US8198402B2 (enExample)
EP (2) EP2078036A2 (enExample)
JP (3) JP5399255B2 (enExample)
KR (1) KR101563010B1 (enExample)
CN (2) CN103435694A (enExample)
AU (1) AU2007329678A1 (enExample)
CA (1) CA2667821A1 (enExample)
MY (2) MY149170A (enExample)
NZ (1) NZ576467A (enExample)
PH (1) PH12013502425A1 (enExample)
SG (2) SG175691A1 (enExample)
WO (1) WO2008070357A2 (enExample)
ZA (1) ZA200902894B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007329678A1 (en) * 2006-10-31 2008-06-12 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Smoothened polypeptides and methods of use
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
PE20091180A1 (es) * 2007-12-27 2009-08-26 Infinity Pharmaceuticals Inc Tratamientos terapeuticos contra el cancer
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
CA2710858A1 (en) 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
AU2010279325B2 (en) 2009-08-05 2016-10-20 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
US20110183948A1 (en) * 2010-01-15 2011-07-28 Infinity Pharmaceuticals, Inc. Treatment of fibrotic conditions using hedgehog inhibitors
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
US9394313B2 (en) 2010-09-14 2016-07-19 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
ES2637113T3 (es) 2011-01-10 2017-10-10 Infinity Pharmaceuticals, Inc. Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
AR088218A1 (es) 2011-07-19 2014-05-21 Infinity Pharmaceuticals Inc Compuestos heterociclicos utiles como inhibidores de pi3k
HK1198443A1 (en) 2011-07-19 2015-04-24 无限药品股份有限公司 Heterocyclic compounds and uses thereof
MX2014002542A (es) 2011-08-29 2014-07-09 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2013337717B2 (en) 2012-11-01 2018-10-25 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
EP2925363A4 (en) 2012-11-29 2016-11-09 Strasspharma Llc METHOD FOR MODULATING FOLLICLE-STIMULATING HORMONACTIVITY
WO2014151386A1 (en) 2013-03-15 2014-09-25 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
CA2914284A1 (en) 2013-05-30 2014-12-04 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
PT3052485T (pt) 2013-10-04 2021-10-22 Infinity Pharmaceuticals Inc Compostos heterocíclicos e suas utilizações
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX382033B (es) 2014-03-19 2025-03-13 Infinity Pharmaceuticals Inc Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR101723649B1 (ko) 2014-10-23 2017-04-06 서울대학교산학협력단 신규한 펩티드 화합물, 이의 생산 방법, 및 이의 용도
PL3302428T3 (pl) 2015-06-04 2026-04-13 Sol-Gel Technologies Ltd. Preparaty do zastosowania miejscowego do dostarczania związków inhibitora hedgehog i ich zastosowanie
WO2017048702A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017139497A1 (en) 2016-02-11 2017-08-17 PellePharm, Inc. Hedgehog inhibitor for use in relief of and treatment of pruritus or itching
JP6889432B2 (ja) * 2016-04-28 2021-06-18 学校法人甲南学園 樹脂固定ペプチド
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG11201811237WA (en) 2016-06-24 2019-01-30 Infinity Pharmaceuticals Inc Combination therapies
CN110520144B (zh) * 2017-02-19 2024-04-05 本-古里安大学B.G.内盖夫技术和应用公司 肽激酶抑制剂及其使用方法
CN108644311B (zh) * 2018-05-22 2019-09-06 东北大学 一种基于硬化立方刚度吸振器实现方法及吸振器
WO2022019920A1 (en) 2020-07-24 2022-01-27 Verastem, Inc. Treatment of cancers using pi3 kinase isoform modulators

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
IN165717B (enExample) 1986-08-07 1989-12-23 Battelle Memorial Institute
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
AU8380898A (en) * 1997-07-01 1999-01-25 Ingham, Philip W Vertebrate smoothened gene, gene products, and uses related thereto
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
US6683192B2 (en) * 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
EP2348047A1 (en) * 2000-04-21 2011-07-27 New England Medical Center G protein coupled receptor (GPCR) agonists and antagonists and methods of activating and inhibiting GPCR using the same
EP1561464A3 (en) * 2001-07-02 2007-04-25 Sinan Tas Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
BR0211513A (pt) * 2001-07-27 2005-08-30 Curis Inc Mediadores de caminhos sinalizantes de hedgehog, composições e usos relacionados ao mesmo
EP1634083A2 (en) * 2003-06-17 2006-03-15 VIB vzw Peptide combos and their uses
JP2008519039A (ja) * 2004-11-04 2008-06-05 ニュー イングランド メデカル センター ホスピタルズ インク Ｇタンパク質共役型受容体アゴニストおよびアンタゴニストならびに使用方法
US8088976B2 (en) * 2005-02-24 2012-01-03 Monsanto Technology Llc Methods for genetic control of plant pest infestation and compositions thereof
WO2007134272A2 (en) * 2006-05-12 2007-11-22 Janssen Pharmaceutica N.V. Humanized models via targeted mtagenesis with zinc finger nuclease
AU2007329678A1 (en) 2006-10-31 2008-06-12 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Smoothened polypeptides and methods of use

Also Published As

Publication number Publication date
PH12013502425B1 (en) 2014-10-27
US8546524B2 (en) 2013-10-01
WO2008070357A9 (en) 2008-08-14
KR101563010B1 (ko) 2015-10-26
ZA200902894B (en) 2010-04-28
CN101616931B (zh) 2013-08-21
US20100093625A1 (en) 2010-04-15
CA2667821A1 (en) 2008-06-12
JP5739484B2 (ja) 2015-06-24
US20130316957A1 (en) 2013-11-28
MY149170A (en) 2013-07-31
AU2007329678A1 (en) 2008-06-12
US8198402B2 (en) 2012-06-12
EP2431388A1 (en) 2012-03-21
SG178743A1 (en) 2012-03-29
WO2008070357A3 (en) 2009-02-26
JP2013255500A (ja) 2013-12-26
JP5399255B2 (ja) 2014-01-29
WO2008070357A2 (en) 2008-06-12
KR20090084839A (ko) 2009-08-05
HK1137031A1 (en) 2010-07-16
MY181496A (en) 2020-12-23
CN101616931A (zh) 2009-12-30
EP2078036A2 (en) 2009-07-15
JP2015180630A (ja) 2015-10-15
CN103435694A (zh) 2013-12-11
US20120282196A1 (en) 2012-11-08
SG175691A1 (en) 2011-11-28
PH12013502425A1 (en) 2014-10-27
JP2010508305A (ja) 2010-03-18

Similar Documents

Publication Publication Date Title
NZ576467A (en) Smoothened polypeptides and methods of use
BRPI0519170A8 (pt) formulações de hormônio de crescimento humano que compreendem um aminoácido não naturalmente codificado
MX2023001466A (es) Enlazadores de base peptidica.
NZ599792A (en) Immunomodulatory polypeptides derived from il- 2 and their use thereof in the therapeutic of cancer and chronic infections
IN2012DN02981A (enExample)
AU2007325952A8 (en) Cell-free synthesis of proteins containing unnatural amino acids
WO2005049073A3 (en) Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients
NZ534919A (en) Bioactive keratin peptides
GB2429207A9 (en) Modified human interferon polypeptides and their uses
GB2436266A (en) Modified human growth hormone
WO2006051110A3 (en) Stable formulations of insulinoptropic peptides
ATE551048T1 (de) Proteinhydrolysate enthaltende kosmetische zusammensetzungen
WO2003070892A3 (en) Inhibitors of rgs proteins
MX2020006822A (es) Proteinas de fusion de anticuerpo de un solo dominio-citosina desaminasa.
EA200601738A1 (ru) Модифицированные белки буганины, цитотоксины и способы их применения
WO2011156453A3 (en) Therapeutic peptides
MX2020013296A (es) Composiciones que contienen inhibidor de proteasa recombinante, metodos para producir las mismas y usos de las mismas.
WO2009064366A3 (en) Methods and compositions for protein labeling using lipoic acid ligases
ATE549353T1 (de) Aktive varianten des il-18 bindenden proteins und dessen medizinische verwendungen
ZA200702938B (en) Peptides and APL-type derivatives of Hsp60 and pharmaceutical compositions
BRPI0707420A8 (pt) composições contendo peptídeos com aminoácidos e métodos não naturais do uso
WO2004113386A3 (en) Modified hirudin proteins and t-cell epitopes in hirudin
WO2007101222A3 (en) Cancer treatment
ATE484290T1 (de) Peptid mit antitumoraler wirkung
ATE510009T1 (de) Förderung der peroxisomalenkatalasefunktion in zellen

Legal Events

Date Code Title Description
PSEA Patent sealed
LAPS Patent lapsed